Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To describe the trends of type 1 diabetes(T1D) incidence in 0-17-year-olds over the years 2020-2023, and the COVID-19 vaccination uptake in Lombardy region.
Methods: Data about children and adolescents aged 0-17 years who received a diagnosis of T1D from 2020 to 2023 were extracted from the public computerized registry of the healthcare system of the Lombardy Region (Italy). After calculating the annual T1D incidence, the incidence in 2020, prior to the availability of vaccination, was compared to subsequent years. A separate analysis was conducted for the 12-17 age group, the first to receive vaccination.
Results: One thousand two hundred seventy-three T1D onsets were recorded. The distribution of T1D showed no significant annual variation by sex (p-trend = 0.338), mean age (9 years, p = 0.537) and age distribution (p-trend = 0.563). T1D incidence [95% CI/100.000] did not significantly change comparing 2020 [18.94/100.000 (CI 16.88-21.18)] with 2021 [21.82/100.000 (CI 18.90-23.44)], 2022 [20.77/100.000 (CI 18.59-23.13)] and 2023 [19.68/100.000 (CI 16.61-20.94)]. No differences in incidence were observed in the 12-17 age group during 2021-2023 when COVID-19 vaccination was available when compared to 2020 (p-wald > 0.05). The COVID-19 vaccination coverage was lower in children with diabetes onset compared to the same-age general population (38 vs 42%).
Conclusions: The incidence of T1D in children remained stable during the COVID-19 pandemic, regardless of the uptake of the vaccination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11810005 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0316340 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
B cell dysregulation during acute COVID-19 is transient.
Immunol Lett
September 2025
Department of Bacteriology and Immunology, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; HUS Diagnostic Center, Clinical Microbiology, Helsinki University Hospital, Helsinki,
Background: COVID-19 is still a significant health concern worldwide. B cell responses to COVID-19 have been extensively studied in acute severe disease, but less so during extended follow-up or mild disease. Persisting immunological changes together with herpesvirus reactivations during acute COVID-19 have been suggested as contributing factors for post-acute sequelae of COVID-19 (PASC).
View Article and Find Full Text PDFSpillover of SARS-CoV-2 to Domestic Dogs in COVID-19-Positive Households: A One Health Surveillance Study.
Virus Res
September 2025
Pennsylvania Department of Agriculture, Pennsylvania Veterinary Laboratory, Harrisburg, PA 17110, USA. Electronic address:
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is capable of infecting multiple species through human-to-animal spillover. Human to animal spillovers have been documented both in domestic and wild animal species. Due to close contact in shared households, pet dogs may be at increased risk for contracting the SARS-CoV-2 virus from infected individuals in the same household.
View Article and Find Full Text PDFAdverse events associated with COVID-19 vaccination or diagnosis among pregnant and non-pregnant women in the United States, 2021-2022.
Int J Infect Dis
September 2025
University of San Francisco, Department of Nursing and Health Professions, San Francisco, California, United States; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Department of Epidemiology, Fielding School of Public Health, University of California, Los A
Objectives: To quantify the incidence of adverse events given COVID-19 vaccination and COVID-19 diagnosis in women of reproductive age; to examine pregnancy as a potential risk modifier.
Methods: An exposure-matched cohort study of >1 million women, 11 December 2020-30 September 2022, United States. COVID-19 vaccination, COVID-19 diagnoses, and medically-attended adverse events - including immunologic, neurologic, cerebrovascular, thromboembolic, cardiovascular, respiratory, thrombocytopenic and coagulative events - were identified from inpatient and outpatient medical claims.
Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention.
Lancet Rheumatol
September 2025
Service de Médecine interne et polyvalente, Centre Hospitalier du Haut-Anjou, Château-Gontier, France; Université d'Angers, Inserm, CNRS, MITOVASC, Equipe MitoLab, SFR ICAT, F-49000 Angers, France. Electronic address:
Infections are increasingly recognised as a major cause of morbidity and mortality in patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. We conducted a systematic review to characterise the infectious burden of VEXAS syndrome and propose preventive strategies. We included 57 studies (813 patients) showing that infections in patients with VEXAS syndrome were frequent, severe in 40-60% of cases, and fatal in 6-15% of cases.
View Article and Find Full Text PDFLong-term comparative effectiveness of BNT162b2 vaccine on SARS-CoV-2 infection in adolescents: A register-based real-world study from Denmark.
Public Health
September 2025
Department of Cardiology, Nordsjællands Hospital, University of Copenhagen, Denmark.
Objectives: Contribute to data on the long-term real-world effectiveness of the BNT162b2 vaccine efficacy (VE) in adolescents.
Study Design: This observational study from July 2021 to June 2022 was designed to emulate a target trial.
Methods: Fully vaccinated adolescents 12-15 years of age were matched to unvaccinated adolescents.